Previous 10 | Next 10 |
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...
Image source: The Motley Fool. Genmab A/S (NASDAQ: GMAB) Q1 2020 Earnings Call May 6, 2020 , 12:00 p.m. ET Operator Continue reading
The following slide deck was published by Genmab A/S in conjunction with their 2020 Q1 earnings Read more ...
Genmab (NASDAQ: GMAB ): Q1 GAAP EPS of DKK4.09. More news on: Genmab A/S, Genmab A/S, Earnings news and commentary, Tech stocks news, Read more ...
The FDA approves a subcutaneous formulation of Johnson & Johnson's ( JNJ -1.9% ) multiple myeloma med Darzalex (daratumumab). Originally, the CD38-directed cytolytic antibody was administered via intravenous infusion. More news on: Johnson & Johnson, Halozyme Therapeutics, Inc....
The European Medicines Agency's advisory group CHMP has adopted a positive opinion backing approval of a subcutaneous formulation of Johnson & Johnson's ( JNJ -0.6% ) multiple myeloma med Darzalex (daratumumab). More news on: Johnson & Johnson, Genmab A/S, Healthcare stocks new...
Intro & pipeline Agenus ( AGEN ) is an immuno-oncology ((IO)) company with a deep and diversified pipeline, a technology for novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing. Agenus believes that the...
Deutsche Bank's Depositary Receipts Virtual Investor Conference presentations now available for On-Demand Viewing Canada NewsWire NEW YORK, March 26, 2020 NEW YORK , March 26, 2020 /CNW/ - Deutsche Bank today announced that the presentations from the March 18 th and 19...
NEW YORK , March 26, 2020 /PRNewswire/ -- Deutsche Bank today announced that the presentations from the March 18 th and 19 th Depositary Receipts Virtual Investor Conference ("dbVIC") are now available for on-demand viewing. The event featured presentations from international companie...
Today, we will see why Genmab (GMAB) is an attractive biotech pick in March 2020. Company overview Genmab is a dual-listed biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. The company was founded in 19...
News, Short Squeeze, Breakout and More Instantly...
A look at the top 10 most actives in the United States Innovative Eyewear Inc. (LUCY) rose 78.0% to $0.58749 on volume of 130,454,575 shares Ocean Power Technologies Inc. (OPTT) rose 29.6% to $0.2073 on volume of 51,927,154 shares Cosmos Health Inc. (COSM) rose 64.9% to $1.12 on volume of...
Company Announcement Positive CHMP opinion based on results from the Phase 1/2 EPCORE ® NHL-1 study FL is the second most common type of NHL and accounts for approximately 20-30 percent of all global cases If approved, epcoritamab (TEPKINLY ® ...
2024-06-27 09:00:08 ET Kaveri Pohlman from BTIG issued a price target of $47.00 for GMAB on 2024-06-27 07:34:00. The adjusted price target was set to $47.00. At the time of the announcement, GMAB was trading at $25.67. The overall price target consensus is at $41.80 with...